Dulaglutide vs Mazdutide

Dulaglutide and Mazdutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.

Dulaglutide, marketed as Trulicity, is a GLP-1 receptor agonist that functions by mimicking the action of the incretin hormone GLP-1, which plays a critical role in glucose metabolism. This peptide is characterized by a fusion of a GLP-1 analog with a modified human IgG4 Fc fragment, resulting in a molecular weight of approximately 59,670 g/mol. Its extended half-life of around five days allows for convenient once-weekly administration via a pre-filled pen device. Research indicates that Dulaglutide effectively improves glycemic control in patients with type 2 diabetes, with clinical studies demonstrating average reductions in HbA1c levels ranging from 1.5% to 2.0%. Additionally, significant weight loss has been observed, with participants losing an average of 6-8 kg over 26 weeks. Moreover, cardiovascular outcomes have been positively influenced, as evidenced by reduced rates of major adverse cardiovascular events in long-term studies, highlighting its multifaceted benefits in metabolic health.

Mazdutide (IBI362) is a pioneering dual agonist targeting both GLP-1 and glucagon receptors, developed collaboratively by Innovent Biologics and Eli Lilly. With a molecular weight of 4,563.06 g/mol, Mazdutide presents a unique mechanism by leveraging the appetite-suppressing effects of GLP-1 alongside the energy expenditure and hepatic fat reduction properties of glucagon. Approved by China's NMPA in June 2025 for chronic weight management and subsequently for glycemic control in type 2 diabetes, Mazdutide marks a significant advancement in obesity treatment. Clinical trials have shown that Mazdutide can lead to substantial weight loss, with participants experiencing an average reduction of 10-15% in body weight over a 20-week period. Furthermore, improvements in glycemic control have been reported, with reductions in fasting glucose levels and hepatic fat content, positioning Mazdutide as a promising candidate in the therapeutic landscape for metabolic disorders.

Both Dulaglutide and Mazdutide have been extensively studied within the realm of metabolic health, focusing on their potential to improve glycemic control and promote weight loss. While Dulaglutide has also been investigated for its cardiovascular benefits, showing promise in reducing cardiovascular events among patients with type 2 diabetes, Mazdutide is particularly noted for its dual action, making it a novel approach for weight management. The intersection of their applications underscores the growing interest in peptides as therapeutic agents in addressing obesity and metabolic syndrome, with ongoing research exploring their efficacy in diverse populations and clinical settings.

The safety profiles of Dulaglutide and Mazdutide reveal some commonalities, particularly concerning gastrointestinal (GI) side effects. For Dulaglutide, adverse events such as nausea (12-21%), diarrhea (8-13%), and vomiting (6-12%) are frequently reported, generally occurring in a dose-dependent manner and often resolving within the first few weeks of treatment. Injection site reactions, including erythema and rash, are noted in 1-2% of cases. In the case of Mazdutide, similar GI side effects have been observed, with nausea, vomiting, and diarrhea being prevalent. These adverse events are also dose-dependent and transient. Additionally, an increase in heart rate has been documented, aligning with effects seen in the GLP-1 agonist class. Researchers must consider these safety profiles when designing studies and interpreting results, as they may impact participant adherence and overall treatment outcomes.